272 related articles for article (PubMed ID: 33012446)
1. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma.
Chen VL; Sharma P
Clin Liver Dis; 2020 Nov; 24(4):577-590. PubMed ID: 33012446
[TBL] [Abstract][Full Text] [Related]
2. Clinical biomarkers in hepatocellular carcinoma (HCC).
Donati M; Brancato G; Donati A
Front Biosci (Schol Ed); 2010 Jan; 2(2):571-7. PubMed ID: 20036969
[TBL] [Abstract][Full Text] [Related]
3. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
4. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation.
Gao J; Song P
Drug Discov Ther; 2017; 11(3):168-169. PubMed ID: 28757516
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
6. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
Shimauchi Y; Tanaka M; Kuromatsu R; Ogata R; Tateishi Y; Itano S; Ono N; Yutani S; Nagamatsu H; Matsugaki S; Yamasaki S; Tanikawa K; Sata M
Oncol Rep; 2000; 7(2):249-56. PubMed ID: 10671666
[TBL] [Abstract][Full Text] [Related]
7. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma--a case control study from western Nepal.
Mittal A; Gupta SP; Sathian B; Sreedharan J; Poudel B; Yadav SK; Pandeya DR
Asian Pac J Cancer Prev; 2012; 13(11):5773-5. PubMed ID: 23317255
[TBL] [Abstract][Full Text] [Related]
9. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.
Wang X; Zhang Y; Yang N; He H; Tao X; Kou C; Jiang J
Biomed Res Int; 2020; 2020():5087643. PubMed ID: 33015170
[TBL] [Abstract][Full Text] [Related]
11. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
14. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Fujikawa T; Shiraha H; Yamamoto K
Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
[TBL] [Abstract][Full Text] [Related]
15. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
Carr BI; Guerra V
Dig Dis Sci; 2016 Mar; 61(3):937-47. PubMed ID: 26576554
[TBL] [Abstract][Full Text] [Related]
16. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
17. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines.
Carr BI; Wang Z; Wang M; Wei G
Dig Dis Sci; 2011 Jun; 56(6):1876-83. PubMed ID: 21188521
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network.
Borges KA; Dai J; Parikh ND; Schwartz M; Nguyen MH; Roberts LR; Befeler AS; Srivastava S; Rinaudo JA; Feng Z; Marrero JA; Reddy KR
Contemp Clin Trials; 2019 Jan; 76():49-54. PubMed ID: 30439517
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.
Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Tanaka J; Yoshizawa H
J Gastroenterol; 2011 Apr; 46(4):536-44. PubMed ID: 21132575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
